DURHAM, N.C.and SEATTLE, Jan. 28, 2025 (GLOBE NEWSWIRE) -- . (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissue at ...

One significant advancement is the development of pancreatic islets derived from human pluripotent stem cells (hPSC-islets). These stem-cell-derived islets have shown promise in treating diabetes ...

This is a useful study that seeks to address the role of the TET family of DNA demethylation enzymes in pancreatic beta cell senescence in the context of type 2 diabetes (T2DM). Although the concepts ...

Eledon Pharmaceuticals has a promising anti-CD40L antibody for organ rejection prevention in transplantation. Learn more ...

Fractyl Health is deprioritizing a type 2 diabetes trial in favor of a pivotal study of its endoscopy treatment Revita and ...

Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissue ...

Area and diameter of islets were measured using the AxioVision 3.1 software. Human islets were fixed in Bouin solution or Shandon Zinc Formula-Fixx (Anatomical Pathology International, Runcorn ...

GenScript Biotech, a global biotechnology leader in life science, biologics manufacturing, synthetic biology, and cell therapies announced the successful conclusion of its 2025 JPM Global Forum held ...

Home > Pressemitteilung: On the way to curing type 1 diabetes ... MHH team aims to intervene in the autoimmune process and stop the destruction of insulin-producing beta cells in the pancreas ...

First-in-Human Study Provides Evidence that Sana’s Hypoimmune (HIP) Technology Enables Transplanted Islet Cells to Avoid Immune Rejection and Produce Insulin Without Immunosuppression Results ...

We came across a bullish thesis on Sana Biotechnology, Inc. (SANA) on wallstreetbets Subreddit Page by Intrepid_Web5454. In ...

Circadian oscillation of biological processes has been described in most of the light-sensitive organisms on earth. It ...